scholarly journals Public funding for non-invasive prenatal testing for fetal aneuploidy - It's time

2018 ◽  
Vol 58 (4) ◽  
pp. 385-387 ◽  
Author(s):  
Susannah Maxwell ◽  
Peter O'Leary
2020 ◽  
Vol 56 (S1) ◽  
pp. 183-184
Author(s):  
S. Leonard ◽  
P. Benn ◽  
E. Valenti ◽  
W. Di Nonno ◽  
Z. Demko ◽  
...  

2019 ◽  
Vol 46 (11) ◽  
pp. 781-782
Author(s):  
Dagmar Schmitz

Bunnik and colleagues argued that financial barriers do not promote informed decision-making prior to prenatal screening and raise justice concerns. If public funding is provided, however, it would seem to be important to clarify its intentions and avoid any unwarranted appearance of a medical utility of the testing.


2012 ◽  
Vol 36 (5) ◽  
Author(s):  
Amy Swanson ◽  
Christin Coffeen ◽  
Amy J. Sehnert

AbstractAfter decades of research, non-invasive prenatal testing (NIPT) using maternal blood to determine fetal chromosome status has found its way from the research laboratory into clinical practice, triggering a long-awaited paradigm shift in prenatal care. A variety of methods using sequencing of maternal cell-free DNA (cfDNA) have now been studied, primarily demonstrating their ability to detect the most common fetal aneuploidy, trisomy 21 (T21). The focus of this article is on massively parallel sequencing (MPS) with optimized sequence tag mapping and chromosome quantification, which accurately detects T21 as well as multiple other aneuploidies across the genome. The power of this technique resides in its high precision and reduction of variation within and between sequencing runs. Using MPS, classification of aneuploidy status for a given sample can be reliably assigned from the genetic information alone without the need to factor in other maternal pre-test risk or other clinical variables. Performance of this method has been prospectively demonstrated in a rigorous, blinded, multi-center study in the United States. The findings suggest that MPS can be incorporated into existing prenatal screening algorithms to reduce unnecessary invasive procedures. This technology and key considerations for clinical implementation are discussed.


Author(s):  
Tatsuko Hirose ◽  
Nahoko Shirato ◽  
Mikiko Izumi ◽  
Keiko Miyagami ◽  
Akihiko Sekizawa

AbstractNon-invasive prenatal testing (NIPT) is used worldwide to screen for fetal aneuploidy. Although previous studies on the psychosocial aspects of NIPT have focused on satisfaction regarding the test, we surveyed women who experienced negative emotions after receiving NIPT. From January 2018 to March 2019, we surveyed pregnant women whose NIPT results were negative, one year after the test. Of the 526 respondents, 35 (6.7%) regretted receiving NIPT and blamed themselves for taking it. We assigned this 6.7% of respondents to the negative emotion group. Although, 76.5% of the participants in the negative emotion group reported they would like to take NIPT for their next pregnancy, it was significantly lower as compared to the control group (92%). Furthermore, 31.9% of respondents in the control group reported that they would recommend similar tests to their relatives and friends. Conversely, in the negative emotion group, this proportion was lower at 17.1%. This suggests that guilt over testing may be meaningful. Thus, this study showed that some NIPT examinees regretted taking the test and blamed themselves. Respondents reported experiencing stress, anxiety, and depression even before NIPT affirming that it is important to address pregnant women’s psychosocial status during pre-test genetic counseling.


2014 ◽  
Vol 36 (3) ◽  
pp. 242-244 ◽  
Author(s):  
Rachel Michaelson-Cohen ◽  
Ruth Gershoni-Baruch ◽  
Reuven Sharoni ◽  
Mordechai Shochat ◽  
Yuval Yaron ◽  
...  

2015 ◽  
Vol 35 (13) ◽  
pp. 1347-1352 ◽  
Author(s):  
Wilfried Gyselaers ◽  
Frank Hulstaert ◽  
Mattias Neyt

Sign in / Sign up

Export Citation Format

Share Document